Key regions: Germany, South Korea, France, United States, United Kingdom
The demand for Anti-Coagulants in Russia has been on the rise in recent years, with the market experiencing steady growth.
Customer preferences: Patients in Russia are increasingly turning to Anti-Coagulants as a means of preventing blood clots and reducing the risk of stroke. This trend is particularly evident among the elderly population, who are more susceptible to such conditions. Additionally, the convenience of oral Anti-Coagulants compared to injections is driving demand for these products.
Trends in the market: The Anti-Coagulants market in Russia is expected to continue its growth trajectory, driven by an aging population and increasing incidence of cardiovascular diseases. Furthermore, the increasing availability of novel oral Anti-Coagulants is expected to further boost demand. However, the market is also expected to face challenges such as the lack of reimbursement for certain Anti-Coagulants and the high cost of treatment.
Local special circumstances: The Russian government has been actively promoting the use of generic drugs in order to reduce healthcare costs. This has led to an increase in the availability of generic Anti-Coagulants, which are more affordable for patients. Additionally, the government has implemented a number of initiatives aimed at improving the quality of healthcare services in the country, which is expected to further boost demand for Anti-Coagulants.
Underlying macroeconomic factors: Russia's economy has been recovering from the recession of 2015-2016, with GDP growth expected to reach 3.3% in 2021. This is expected to have a positive impact on the Anti-Coagulants market, as consumers have more disposable income to spend on healthcare. Additionally, the government's focus on healthcare reform is expected to drive growth in the pharmaceutical sector. However, the ongoing COVID-19 pandemic has had a negative impact on the healthcare sector in Russia, with many hospitals facing capacity constraints and delays in elective procedures. This has led to a slowdown in the growth of the Anti-Coagulants market in the short term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
